News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Torc Investments and Research Reiterates "Buy" Rating on Generex Biotechnology Corporation (GNBT) and $3.00-$3.50 12-Month Price Target



3/20/2007 10:16:04 AM

TORONTO -- (MARKET WIRE) -- March 20, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Torc Investments and Research LLC, a NASD registered broker-dealer, reiterated its Buy rating and a 12-month price target of $3-$3.50.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES